Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Cancer Lett. 2022 Jun 10;543:215779. doi: 10.1016/j.canlet.2022.215779

Figure 5: Versican secreted from the ovary drives migration of fallopian tube epithelial cells.

Figure 5:

Migration analysis of (A) MOE and (B) FT33-TAg cells treated with human recombinant versican (0–100 ng/ml) after 24h. Wound healing assay in (C) MOE and (D) FTE 33Tag cells treated with versican and 1 μM EGFR inhibitor after 24h. Migration analysis of MOE cells (E) and FT33-Tag (F) incubated with recombinant versican for 24h with and without EGFR inhibitors PD158780 10 μM or Erlotinib 10 μM (EUR). A minimum of three independent experiments, biological replicates were analyzed using one-way ANOVA (ns>0.05, p*<0.05, p**<0.01, ***, ****).